Local drug delivery to prosthetic vascular grafts: Preventing failure of prosthetic grafts in haemodialysis patients

Dr Ronald J. Shebuski, President and CEO of Cylerus, Inc., wants to revolutionise the way vascular grafts work. His company, Cylerus, has an innovative way to deliver an antiproliferative drug, sirolimus, in a consistent and controlled manner. This method of drug delivery, via a porous graft material called ePTFE, has the potential to reduce failure of arterio-venous access grafts crucial for […]

Read More…

Thank you for expressing interest in joining our mailing list and community. Below you can select how you’d like us to interact with you and we’ll keep you updated with our latest content.

You can change your preferences or unsubscribe by clicking the unsubscribe link in the footer of any email you receive from us, or by contacting us at audience@researchoutreach.org at any time and if you have any questions about how we handle your data, please review our privacy agreement.

Would you like to learn more about our services?

We use MailChimp as our marketing automation platform. By clicking below to submit this form, you acknowledge that the information you provide will be transferred to MailChimp for processing in accordance with their Privacy Policy and Terms.

Subscribe to our FREE PUBLICATION